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A B S T R A C T
Background: Disulﬁram (DSF) is a drug used for treatment of alcoholism that has also displayed promising anti-
cancer activity. It unfolds its eﬀects by inhibiting the enzyme activity of aldehyde dehydrogenase (ALDH) iso-
forms.
Methods: MTT assay, spheroid formation, clonogenicity assay, qRT-PCR, and ALDH enzyme activity analysis
were performed using ovarian cancer cell lines IGROV1, SKOV3 and SKOV3IP1. Cell cycle analyses and mea-
surement of intracellular reactive oxygen species (ROS) were carried out by ﬂow cytometry. ALDH+ and
ALDH− cells were isolated by FACS sorting.
Results: ALDH activity was inhibited in ovarian cancer stem cells (the proportion of ALDH+ cells was reduced
from 21.7% to 0.391%, 8.4% to 0%, 6.88% to 0.05% in cell lines IGROV1, SKOV3, and SKOV3IP1, respectively).
DSF with or without the cofactor copper (Cu2+) exhibited cytotoxicity dose- and time-dependent and enhanced
cisplatin-induced apoptosis. DSF+Cu2+ increased intracellular ROS levels triggering apoptosis of ovarian
cancer stem cells (CSC). Signiﬁcantly more colony and spheroid formation was observed in ALDH+ compared
with ALDH- cells (P < 0.01). Moreover, ALDH+ cells were more resistant to cisplatin treatment compared with
ALDH-cells (P < 0.05) and also exhibited a lower basal level of ROS. However, no signiﬁcant diﬀerence in ROS
accumulation nor in cellular viability was observed in ALDH+ cells in comparison to ALDH- cells after pre-
treatment with DSF (0.08 μM).
Conclusion: Our ﬁndings provide evidence that DSF might be employed as a novel adjuvant chemotherapeutic
agent in combination with cisplatin for treatment of ovarian cancer.
1. Introduction
Epithelial ovarian cancer (EOC) is the most lethal gynaecological
cancer [1]. Although many patients initially beneﬁt from surgery and
chemotherapy [2,3], recurrent disease develops in more than 80% of
patients with advanced stage and 25% of early stage ovarian cancer [4].
Currently, systemic administration of platinum-based chemotherapy
following surgery is currently the best standard of care. Unfortunately,
cancer cells, either intrinsically have or acquire resistance to cisplatin-
based chemotherapy, leading to relapse and therapeutic failure [5]. It
has been observed that around 50% of the patients relapse within 5
years [6]. Cancer stem cells (CSCs), which are deﬁned by two key
characteristics, enhanced tumorigenicity and the capacity for self-re-
newal/diﬀerentiation [7], are thought to contribute to drug resistance
and cancer recurrence. There are several suggested mechanisms for the
chemo-resistance of CSCs. First, traditional chemotherapeutic agents
typically induce apoptosis by damaging DNA and inhibiting cell cycle
distribution. However, CSCs which are a proliferative quiescent and
slowly-cycling cell population are therefore less sensitive to treatment.
Second, there is increased activation of the DNA damage checkpoint
response in CSCs and third, CSCs show enhanced expression of trans-
porters, which help eﬄux chemotherapeutic drugs. Since CSCs account
for the unsatisfactory low response rate of tumors to chemotherapy, it
remains a priority to increase the sensitivity of cisplatin-based
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chemotherapy or to recognize and target speciﬁcally CSCs to improve
the outcome of ovarian cancer patients.
Although most ovarian cancer patients initially respond to che-
motherapy, there is a small subpopulation of cells (generally less than
2% of the tumor cells) which are resistant to initial adjuvant therapy
and hence ﬁnally leads to recurrence of the disease [8,9]. Bapat et al.
were the ﬁrst who cultured ovarian cancer stem cells from the ascites of
an ovarian cancer patient [10]. They isolated a single tumorigenic clone
from the mixed ascites cells, which showed diﬀerentiation features and
was able to give rise to new tumors when transplanted into mice. In-
creasing evidence suggested that CSCs might be an explanation for
chemo-resistance and the recurrence of ovarian cancer. Several poten-
tial CSC markers have been used to identify CSCs in ovarian cancer,
such as CD44, c-kit, CD133, and ALDH, and there is certainly an overlap
in the expression of these markers [11]. However, ALDH holds the at-
tractive distinction among these markers as ALDH may be more than
just a CSC marker but may have a potential functional role in CSC
biology [12]. Studies have shown that ALDH enzyme expression and
activity may be associated with particular cell types in ovarian tumor
tissues and vary according to cellular states [13], indicating that ALDH
isozymes may play essential roles in lineage diﬀerentiation and pa-
thogenesis for ovarian cancer pathophysiology [14].
The ALDH enzymes are a family comprised of 19 isoforms that are
localized in the cytoplasm, mitochondria, or nucleus. The ALDH en-
zymes in immunohistochemistry (IHC) and ALDH activity in ﬂow cy-
tometry are widely used as a CSC marker for many malignancies such as
leukemia, lung, liver, bone, prostate, head and neck, ovarian cancer,
and cervical cancer [15–17]. Increased ALDH activity, as measured by
ALDEFLUOR assay, is also commonly used for the isolation of CSCs.
ALDH family members play essential roles in a variety of biological
activities in CSCs, including diﬀerentiation, oxidative stress response,
and drug resistance [18]. Tumor cells with higher ALDH activity or
ALDH positive cells sorted form primary tumor cells have been de-
monstrated to have enhanced tumorigenicity, and increased migratory
capacity [15–17]. Additionally, studies have shown that ALDH can
decrease intracellular oxidative stress as it functions as a ROS scavenger
[17,19]. Thus, ALDH activity is required to maintain suﬃciently low
ROS levels and prevent triggering CSC apoptosis [20]. Potentially,
ALDH could protect cancer stem cells against oxidative stress induced
by alcohol, UV radiation, and some chemotherapeutic agents [21].
Moreover, there is a potential role for ALDH in CSC resistance to che-
motherapy. Studies have indicated that some CSC populations express
signiﬁcantly elevated levels of ALDH in conjunction with resistance to
conventional chemotherapy [22].
Disulﬁram (DSF), a member of the dithiocarbamate family, is a
FDA-approved drug that has been used for the clinical treatment of
alcoholism for over 60 years [23]. Recent studies demonstrate that DSF
has potent anticancer activity in vitro and in cancer xenografts [24–28],
highlighting it as a potential novel chemotherapeutic agent. However,
the exact mechanism of action as a cytotoxic agent in cancer cells is still
unclear. Importantly, Chen et al. initially reported that DSF-copper
complexes could potently inhibit the activity of the proteasomes and
induce apoptosis in cultured breast cancer cells [24]. Here we explored
the inhibitory eﬀect of DSF on ALDH, and the eﬀect of DSF on ALDH+
stem-like cells after cell sorting, and the potential underlying mechan-
isms. The presented experiments demonstrated that ALDH could be a
therapeutic target in CSCs. The results showed that ALDH plays an es-
sential role in cisplatin resistance. DSF combined with cisplatin over-
comes cisplatin-resistance in ALDH+ stem-like cells and achieves the
same level of ROS accumulation in ALDH+ and ALDH- cells.
2. Materials and methods
2.1. Cell culture
The ovarian cell lines IGROV1, SKOV3, and SKOV3IP1 were
cultured in RPMI 1640 medium with L-glutamine (Invitrogen,
Heidelberg, Germany) supplemented with 10% fetal bovine serum and
1% penicillin/streptomycin (both from Millipore, Darmstadt, Germany)
in a humidiﬁed incubator at 37 °C and 5% CO2. All experiments were
performed on cultures that were 70% conﬂuent. Three cell lines were
chosen due to their diﬀerent degrees of sensitivity to DSF treatment.
2.2. Spheroid formation assay
To generate spheroids, cells were seeded in 24-well Ultra-Low
Attachment plates (Corning, New York, USA) at a speciﬁc density of
2× 104 cells/ml in Quantum 263 medium (PAA, Cöllbe, Germany)
supplemented with 10 ng/ml Epidermal Growth Factor (EGF) and
10 ng/ml Fibroblast Growth Factor-basic (FGF) (Millipore). Cells were
allowed to grow for 10–14 days to form spheroids. For passaging, all
spheroids were collected with a 40 μm mesh ﬁlter and centrifuged at
1500 rpm for 5min. Spheroids were dissociated into single cells using
trypsin/EDTA (Millipore) at 37 °C at 5% CO2 for 5min, followed by
washing with PBS twice. Single cells were reseeded in fresh culture
medium under the same conditions. After passaging the spheroids into
2nd or 3rd generation, spheroid-derived cells were treated with DSF or
DSF+Cu2+ in a 96-well ultra-low attachment plate (200 cells in 0.2ml
medium/well) for 7–10 days and photographed at 50 fold magniﬁca-
tion. Spheroids were counted when the diameter of spheroids was more
than 100 μm.
2.3. MTT assay
Cells were seeded in 96-well plates at a density of 4000 cells per
well in 100 μl cell culture medium and incubated overnight. Then
culture medium was removed, and cells were exposed to drugs at var-
ious concentrations. Free DSF was dissolved in DMSO at a storage
concentration of 10mM and diluted to working concentrations in
medium before use. The absorbance was measured at a wavelength of
590 nm with a Bio-Rad microplate reader after 72 h incubation.
Relative viability (%) of cells was calculated according to the following
equation: Relative viability (%)= (A sample/A control) *100%, where
A sample and A control were the absorbance of the sample and control
wells, respectively. Dose-response curves and IC50 were calculated
using GraphPad Prism 5.04 (GraphPad Software Inc., La Jolla, CA,
USA).
2.4. Flow cytometric analysis of cell cycle
Analysis of cell cycle progression and detection of apoptosis was
performed using ﬂow cytometric analysis of DNA staining. All drug-
treated and untreated cells were harvested by trypsinization. Cells
(4*104/well) were suspended in 100 μl PBS and ﬁxed in 900 μl 70%
ethanol overnight. The cells were then incubated with RNase (100 μg/
ml, Sigma, Darmstadt, Germany) and propidium iodide (50 μg/ml,
Sigma, Darmstadt, Germany) for 30min. The data from 10,000 cells for
each sample were acquired by FACS Scan (BD Bioscience, Heidelberg,
Germany) and DNA content and cell cycle distribution was analyzed.
2.5. Apoptosis assessment
Apoptotic status was determined by FLUOS-conjugated Annexin-V
and propidium iodide Kit (Roche, Mannheim, Germany) using ﬂow
cytometry following the manufacturer’s instructions. Cells (4*104/well)
were incubated in a 24-well plate overnight and treated with drugs for
further 72 h. All cells were then harvested and suspended in 100 μl
binding buﬀer containing FITC-conjugated Annexin-V (2 μl)/PI (2 μl)
and incubated at RT for 15min. Apoptosis and necrosis were evaluated
using FL3 (PI) and FL1 (Annexin-V) by FACS analysis. The percentage
of cells were determined in four quadrants: live cells, (Annexin-V−/
PI−, lower/left quadrant); early apoptotic cells (Annexin-V+/PI−,
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lower/right quadrant); late apoptotic cells (Annexin-V+/PI+, upper/
right quadrant); and necrotic cells (Annexin-V−/PI+, upper/left
quadrant), respectively.
2.6. Clonogenicity assay
Cells were exposed to DSF (1 μM), Cu2+ (1 μM), or DSF (1 μM)/
Cu2+ (1 μM) for 24 h. The drug-treated cells were then collected and
cultured in drug-free medium in a 6-well plate at a density of 2000
cells/well for 7–10 days. Fixation and staining of colonies were done by
adding 2–3ml of a mixture of 6.0% glutaraldehyde and 0.5% crystal
violet. Colonies of at least 50 cells were counted and compared with
non-treated cells as controls.
2.7. Flow cytometric analysis of ALDH activity and sorting
ALDH activity was assessed using the ALDEFLUOR kit (Stem Cell
Technologies, Durham, NC, USA). Brieﬂy, cells (4*104/well) were in-
cubated with ALDH substrate BAAA for 30min at 37 °C following the
manufacturer’s instructions. Tested cells were exposed to DSF (10 μM),
Cu2+ (1 μM), DSF (10 μM) + Cu2+ (1 μM). Cells treated with diethy-
laminobenzaldehyde (DEAB), a speciﬁc ALDH inhibitor, were used as a
control to establish the baseline ﬂuorescence and deﬁne the cut oﬀ for
ALDEFLUOR-positive cells.
For FACS sorting, cells were re-suspended in PBS buﬀer at a con-
centration of 1×107 cells/ml and separated on an Aria cell sorter (BD
Biosciences). The sorted cells were exposed to DSF for 30min, and re-
active oxygen species (ROS) activity was analyzed by FACS (methods
described below). The sorting gates were established with negative
controls that were treated with DEAB.
2.8. Measurement of ROS
Mitochondrial ROS was measured using the Mitosox Red kit
(Invitrogen, Paisley, UK). Cells were treated with Cu2+ (1 μM), DSF
(10 μM), DSF (10 μM)+Cu2+ (1 μM), DSF (100 μM), or DSF
(100 μM)+Cu2+ (1 μM) for 30min, harvested and analyzed by ﬂow
cytometry. Cells with Mitosox Red reagent, but no drug treatment, were
used as control. All samples were normalized to untreated control, and
relative ROS activity was determined. ROS activity after cells sorting
was also determined. Gates were set for the percentage of mitochon-
drial ROS in control cells, and the same gate was used on treated cells to
quantitate the induction of ROS.
2.9. Statistical analysis
The statistical analysis of data in this study was performed with
GraphPad Prism 5.04 (GraphPad Software Inc., La Jolla, CA, USA) using
one-way ANOVA test. Diﬀerences were considered signiﬁcant at
P＜ 0.05.
3. Results
3.1. DSF+Cu2+ displays cytotoxic eﬀects on ovarian cancer cell lines
Initially, the cytotoxic eﬀect of DSF on three ovarian cancer cell
lines was examined using MTT assay to determine the IC50 of cyto-
toxicity to each cell line. The reduction in viability, as measured by
MTT assay, represents the reduced metabolic rate after DSF treatment.
As shown in Fig. 1A, the proliferation of cells was signiﬁcantly inhibited
after exposure to concentrations of DSF between 0.001 μM and 100 μM
for 72 h. Dose-dependent cytotoxicity was observed in all three ovarian
cancer cell lines. DSF showed a linear increase of cytotoxicity with
increasing concentration of the drug in SKOV3 cells, and biphasic cy-
totoxicity in IGROV1 and SKOV3IP1 cell lines, with the relative viabi-
lity of cells increasing slightly at DSF 10 μM (Fig. 1A). IC50 values for
these three cell lines were IGROV1 IC50: 2.01 ± 0.11 μM; SKOV3 IC50:
0.19 ± 0.09 μM; SKOV3IP1 IC50: 10 ± 2.48 μM, showing variable
sensitivity of the three cell lines investigated towards treatment
(Table 1).
We next examined the apoptosis induced over time after treatment
with DSF in a time-course experiment. The cells were exposed to a
speciﬁc concentration according to their IC50 (IGROV1 and SKOV3IP1:
DSF 1 μM; SKOV3: DSF 0.1 μM) for 4–72 h. The fraction of apoptotic/
necrotic cells is represented by Annexin V / PI positive cells, and this
fraction contributes to overall lower metabolic activity. As shown in
Fig. 1B, both early apoptosis (Annexin-V+/PI−, lower/right quadrant)
and late apoptosis (Annexin-V+/PI+, upper/right quadrant) increased
with time of treatment. The control cells were cultured for 72 h without
treatment showed less apoptosis than drug-treated cells. These results
indicate that DSF itself is cytotoxic in a dose- and time-dependent
manner around the concentration of their IC50 with some variation
between the three investigated cell lines.
Moreover, the DSF+Cu2+ combination enhances the cytotoxicity
on ovarian cancer cell lines. As shown in Fig. 1F, no signiﬁcant cyto-
toxicity was observed in cells treated with Cu2+ alone until the con-
centration of Cu2+ increased from 10 μM to 100 μM. Therefore, a
concentration of 1 μM of Cu2+ in combination with DSF was chosen.
Although DSF alone had signiﬁcant eﬀects, the cytotoxicity of DSF was
signiﬁcantly enhanced in Cu2+ (1 μM)-supplemented medium in all
ovarian cancer cell lines. Treatment with DSF at diﬀerent doses in
combination with 1 μM Cu2+ for 72 h signiﬁcantly inhibited the cell
viability as compared to DSF treatment alone. Interestingly, in the
presence of 1 μM Cu2+, as low as 0.1 μM DSF showed strong cytotoxi-
city (Fig. 1F). Fig. 1G shows that both early apoptosis (Annexin-V
+/PI−, lower/right quadrant) and late apoptosis (Annexin-V+/PI+,
upper/right quadrant), as well as necrosis (Annexin-V−/PI+, upper/
left quadrant), increased with DSF+Cu2+ treatment compared to DSF
exposure alone. Cu2+ reduced IC50 at 72 h of treatment with DSF about
10–100 fold (Table 1).
3.2. Inhibitory eﬀect of DSF+Cu2+ on ovarian cancer cell lines
One of the accepted assays to evaluate the stemness of cells is the
ability of epithelial cells to grow anchorage independently. In this
study, spheroid culture models were used to enrich CSCs. Results
showed that the expression of stemness-related nuclear transcription
factor (TF) Oct3/4, Sox2, and Nanog is higher in spheroid-derived cells
than monolayer-derived cells (supplemental Fig. 1), indicating that
spheroid culture models could be used to assess CSCs. Also, spheroid-
derived cells showed higher IC50 of cisplatin treatment, demonstrating
that spheroid-derived cells were more resistant to cisplatin (Table 2).
Fig. 2A shows an abundance of large spheroids grown from untreated
control cells. However, the ability of ovarian cancer cells to form
spheroids when exposed to DSF was reduced, showing only cellular
aggregates, suggesting reduced proliferative potential of the stem cells.
When DSF combined with 1 μM Cu2+ was applied, only diﬀuse in-
dividual cells were seen in DSF+Cu2+-treated samples and spheroid
formation in all three cell lines was completely abolished (Fig. 2A).
Fig. 2B shows that the number of spheroids was signiﬁcantly reduced
from average 71 to 0 in IGROV1, from average 16 to 0 in SKOV3, and
from 38 to 0 in SKOV3IP1 when the cells were exposed to DSF or
DSF+Cu2+ (P＜ 0.01) as compared to the untreated control cells.
Although the number of spheroids was slightly reduced in Cu2+-treated
cells, there was no statistically signiﬁcant diﬀerence compared to
control cells.
Next, a clonogenicity assay was performed to test the ability of
every cell in the population to undergo “unlimited” divisions to de-
termine cell reproductive capacity after drug treatment. Cells were pre-
treated with DSF (1 μM) or Cu2+ (1 μM), respectively, and in combi-
nation with DSF (1 μM) + Cu2+ (1 μM) for 24 h, and sub-cultured in
drug-free medium for another 7–10 days. As shown in Fig. 2C, the
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colony number in the Cu2+ (1 μM) treated group was decreased as
compared to control cells that had not been treated. This was caused by
a slowed growth of surviving cells and resulted in smaller colonies that
did not reach the counting threshold (diameter of spheroids had to be
more than 100 μm per colony to be counted). The colony number was
signiﬁcantly reduced by DSF (1 μM) treatment of cells with colony-
forming units from around 700 in control to 200 in SKOV3 cell line and
from around 1000 in control to 500 in IGROV1 and SKOV3IP1 cell lines
Fig. 1. DSF+Cu2+ displays cytotoxic eﬀects on ovarian
cancer cell lines. A) MTT assay. The ovarian cancer cell
lines were exposed to diﬀerent concentrations of DSF for
72 h and viability related to untreated control. B)
Representative data for ﬂow cytometric analysis of
Annexin-V/PI staining after exposure to DSF for diﬀerent
treatment intervals. C–E) Graphical representation of the
statistical analysis of the Annexin-V/PI dual staining re-
sults. F) MTT assay. The ovarian cancer cell lines were
exposed to diﬀerent concentrations of DSF combined
with 1 μM Cu2+ for 72 h and viability related to un-
treated control. G) Annexin-V/PI assay. IGROV1 and
SKOV3IP1 cells were exposed to 1 μM DSF alone, 1 μM
Cu2+ alone, and 1 μM DSF+1 μM Cu2+ for 72 h. SKOV3
cells were exposed to 0.1 μM DSF alone, 1 μM Cu2+
alone, and 0.1 μM DSF+1 μM Cu2+ for 72 h. H–J)
Graphical representation of the statistical analysis of the
Annexin-V/PI dual staining results. Cells without any
drug treatment were used as control. One representative
of three independent experiments is shown. Statistical
analyses are based on three independent experiments.
*P＜ 0.05, **P＜ 0.01, ***P＜ 0.0001.
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(P＜ 0.05). The colony-forming ability of ovarian cancer cells was al-
most totally eradicated by DSF (1 μM)+Cu2+ (1 μM) treatment in
SKOV3 and SKOV3IP1 cell lines. There is also a signiﬁcant diﬀerence
between cell cultures treated by DSF alone and DSF+Cu2+ treated
cultures (Fig. 2C). These results indicated that DSF or DSF in conjunc-
tion with Cu2+ was able to suppress the clonogenicity of ovarian cancer
cells.
As ALDHs are essential for maintenance and diﬀerentiation of stem
cells as well as normal development, and increased ALDH activity has
been found to relate to stemness of CSCs as well as chemotherapy re-
sistance, we wanted to determine whether DSF or DSF+Cu2+ could
inhibit the activity of the aldehyde dehydrogenase enzymes measured
by ALDEFLUOR assay. Fig. 2D shows that DSF signiﬁcantly reduced the
proportion of ALDH+cells (from 21.7% to 0.391% in IGROV1 cell
line, 8.4% to 0 in SKOV3 cell line, 6.88% to 0.05% in SKOV3IP1 cell
line), while Cu2+ alone did not aﬀect the ALDH+population. In
comparison with control cells that had not been drug treated, the
ALDH+population was abolished in ovarian cancer cell lines in-
cubated with DSF (10 μM)+Cu2+ (1 μM) (Fig. 2D). The result also
demonstrated that ALDH activity in ovarian cancer cells was not only
inhibited by diethylaminobenzaldehyde (DEAB), a speciﬁc ALDH in-
hibitor, but also inhibited by DSF with or without Cu2+ supplementa-
tion. Moreover, the inhibitory eﬀect by DSF was better than that of
DEAB, while Cu2+ supplementation even enhanced this inhibitory ef-
fect compared to DSF treatment alone.
3.3. No signiﬁcant cell cycle changes are induced by DSF+Cu2+
Cell cycle analysis was performed by ﬂow cytometry and assessed
by propidium iodide staining of DNA. Firstly, the cells were treated
with a higher concentration of DSF at the same concentration like in the
Annexin-V/PI assay (1 μMDSF alone, 1 μM Cu2+ individually, and 1 μM
DSF+1 μM Cu2+ for IGROV1 and SKOV3IP1 cells; 0.1 μM DSF alone,
1 μM Cu2+ individually, and 0.1 μM DSF+1 μM Cu2+ for SKOV3
cells). As shown in Fig. 3A (upper rows a and b), a more massive sub-G1
peak was induced by the DFS+Cu2+ combination than by DSF alone
in the treated cells. These results were in agreement with the Annexin-
V/PI assay showing that the DFS+Cu2+ combination induced more
apoptosis than DSF alone. However, since the cell cycle phases were
compromised and disappeared at this high drug concentration analysis
of the cell cycle was not possible. In order to display the cell cycle
distribution while avoiding excessive apoptosis during prolonged ex-
posure, cells were treated with DSF at a lower concentration (0.01 μM
DSF alone, 1 μM Cu2+ alone, and 0.01 μM DSF+1 μM Cu2+ for 72 h
for three cell lines). The DFS concentration was selected according to
the sensitivity of the cell lines in the speciﬁc assays to be able to
measure and determine the diﬀerent eﬀects on apoptosis and pro-
liferative activity. As shown in Fig. 3A (lower rows c–f) the proportion
of cells in the G1 phase, S phase, and G2-M phase did not signiﬁcantly
change although there is some variation with diﬀerent treatments
compared to untreated control cells (Fig. 3B–D). Cells treated with
other concentrations of DSF were also assessed to further illustrate the
cell cycle distribution. Cells treated with cisplatin, which arrests cell
cycle at G2/M phase were used as a positive control (Supplemental
Fig. 2). These results indicated that DSF with or without Cu2+ had no
signiﬁcant eﬀect on cell cycle at relatively lower concentrations.
3.4. DSF+Cu2+ enhances the generation of ROS
ROS are involved in cancer development and metastasis. We have
shown that DSF inhibits ALDH activity which generally acts as a ROS
scavenger to protect cells against oxidative stress. Consequently, it is
meaningful to further investigate if the underlying mechanisms of DSF
toxicity are based on ROS accumulation. Cells were treated as described
in the method section, and mitochondrial ROS was measured by ﬂow
cytometry. The results showed that DSF, with or without Cu2+ sup-
plementation, signiﬁcantly induced more ROS activity in all three
ovarian cancer cell lines. The relative ROS activity after normalization
to untreated control cells was increased by 19.4 fold in IGROV1 cells,
2.98 fold in SKOV3 cells, and 2 fold in SKOV3IP1 cells by treatment
with 10 μM DSF (Fig. 4A). More ROS was generated when the DSF
concentration was increased from 10 μM to 100 μM. The relative ROS
activity after normalization to untreated control cells was signiﬁcantly
increased by 64.9 fold in IGROV1 cells, 99.4 fold in SKOV3 cells, and
51.2 fold in SKOV3IP1 cells when incubated with 100 μM DSF. With the
same concentration of DSF, more ROS was induced by supplementation
with Cu2+ (1 μM) as compared to DSF treatment alone (Fig. 4A–D). As
shown in Fig. 4E, ALDH+cells exhibited a lower basal level of ROS
due to higher levels of ALDH expression. However, no signiﬁcant dif-
ference in ROS generation in ALDH+/− cells was observed after DSF
(10 μM) treatment. When DSF concentration was increased to 100 μM,
ROS levels decreased in ALDH+ cells (Fig. 4E). So the explanation
could be that ALDH+ cells were probably more vulnerable to DSF and
were swiftly killed by this concentration.
3.5. DSF sensitizes cancer cells to cisplatin treatment and enhances
cisplatin-induced apoptosis
To investigate whether DSF sensitizes cancer cells to cisplatin
treatment, we tested the cell viability after treatment with DSF alone
(IGROV1: 0.1 μM; SKOV3: 0.08 μM; SKOV3IP1: 1 μM) or cisplatin alone
(IGROV1: 1 μM or 5 μM; SKOV3: 0.2 μM or 0.4 μM; SKOV3IP1: 1 μM or
5 μM) or in combination. Fig. 5A shows that exposure to either DSF or
cisplatin alone for 72 h only slightly reduced the cellular viability.
However, a signiﬁcant decrease of cellular viability was induced by the
drug combinations compared to individual treatment with DSF or cis-
platin (P＜ 0.01) at these concentrations. The results indicate that DSF
sensitizes cancer cells to cisplatin treatment even at lower doses, with
decreased cell viability of 50–80% in the three cell lines. To further
determine whether DSF sensitizes for cisplatin treatment and sup-
presses cell viability by inducing apoptosis, we tested the apoptotic
status by ﬂow cytometry using Annexin-V (FITC) and propidium iodide
(PI) staining. Cells were treated with DSF alone (IGROV1 and
SKOV3IP1: 1 μM; SKOV3: 0.05 μM) or cisplatin alone (IGROV1 and
SKOV3IP1: 5 μM; SKOV3: 0.3 μM) or in a combination for 72 h. The
results showed that in the IGROV1 cell line early apoptosis increased
from 0.893% to 6.42%, late apoptosis increased from 4.15% to 19.8%,
and necrosis increased from 2.11% to 2.74% in control cells and in cells
treated with cisplatin alone, respectively. However, a signiﬁcant in-
crease in cellular apoptosis and necrosis was induced when 1 μM DSF
was combined with cisplatin, with early apoptosis and late apoptosis
reached to 16.7% and 31.4%, respectively. Importantly, treatment with
1 μM DSF did not induce more cellular apoptosis and necrosis compared
to control cells. Similar results were observed in the SKOV3 and
SKOV3IP1 cell lines. In SKOV3 cells, early apoptosis, late apoptosis, and
Table 1
IC50 of three ovarian cancer cell lines treated by DSF or DSF/Cu2+ for 72 h.
DSF DSF/Cu
IGROV1 2.01 ± 0.11 μM 0.2 ± 0.07 μM
SKOV3 0.19 ± 0.09 μM 0.02 ± 0.01 μM
SKOV3IP1 10 ± 2.48 μM 0.1 ± 0.09 μM
Table 2
IC50 of MDCs and SDCs treated by cisplatin for 72 h.
MDCs SDCs
IGROV1 10 ± 1.8 μM 40 ± 2 μM
SKOV3 1.0 ± 0.5 μM 3.0 ± 0.1 μM
SKOV3IP1 12 ± 0.1 μM 15 ± 1.0 μM
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necrosis increased from 6.52%, 5.02%, and 2.45% in cisplatin-treated
cells to 30.4%, 13.9% and 2.61%, respectively, in the drug combination
of DSF plus cisplatin. In SKOV3IP1 cells, early apoptosis, late apoptosis,
and necrosis increased from 4.77%, 9.34%, and 0.617% in cisplatin-
treated cells to 8.53%, 23%, and 1.76%, respectively, in the drug
combination (Fig. 5B). These results indicate that DSF enhanced cis-
platin-induced cellular apoptosis in ovarian cancer cell lines.
Fig. 2. Inhibitory eﬀect of DSF+Cu2+ on ovarian cancer cell
lines. A) DSF inhibited spheroid formation. Cells were treated
with 0.1 μM DSF or 1 μM Cu2+ or 0.1 μM DSF+1 μM Cu2+ in
ultra-low attachment 96-well plates for 7–10 days and pho-
tographed (magniﬁcation 50 fold). B) Cells were exposed to
drugs for 10 days, and spheroids with ≥100 μm in diameter
were counted, and their numbers per well (n= 8) were
plotted. C) Clonogenicity assay. Cells exposed to 1 μM Cu2+
alone, 1 μM DSF alone, or 1 μM DSF+1 μM Cu2+ for 24 h
were cultured in drug-free medium in six-well plates at a cell
density of 2000 cells per well for 7–10 days. The colonies were
counted. D) DSF+Cu2+ inhibits ALDH activity. Cells were
exposed to DSF (10 μM), Cu2+ (1 μM), or DSF
(10 μM)+Cu2+ (1 μM). Cells treated with diethylamino-
benzaldehyde (DEAB), which is a speciﬁc ALDH inhibitor,
were used as control. Numbers represent ALDH+ cells (%).
One representative of three independent experiments is
shown. E) Graphical representation of the statistical analysis
of ALDH activity (n= 3). Statistical analyses are based on
three independent experiments. *P＜ 0.05, **P＜ 0.01,
***P＜ 0.001, ****P＜ 0.001.
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3.6. DSF enhances cisplatin cytotoxicity in ALDH+ cells
To assess the impact of ALDH expression in CSCs further, FACS-
sorted ALDH+and ALDH− cells from cell line SKOV3 were cultured
for 10 days and the colony and spheroid formation assays were per-
formed. As shown in Fig. 6A–D, signiﬁcantly more colony and spheroid
formation was observed in ALDH+ cells compared to ALDH- cells
(P < 0.01). Remarkably, the number of colonies and spheroids was
increased in ALDH+cells compared to ALDH- cells. These results
conﬁrm the importance of ALDH activity in CSCs.
ALDH+cells and ALDH- cells were then treated with cisplatin at
indicated concentrations for 72 h and subjected to MTT assay. As shown
in Fig. 6E, ALDH+ cells were more resistant to cisplatin treatment
compared to ALDH− cells at any concentration investigated. The
relative cellular viability was signiﬁcantly higher in ALDH+ cells than
ALDH− cells after cisplatin treatment at the same concentration
(P < 0.05). These results indicate that ALDH+ cells display stem-like
characteristics, such as sustained proliferation capability and resistance
to chemotherapy. However, when the cells were pre-treated with DSF
(0.08 μM) for 24 h, following incubation with cisplatin plus DSF, no
signiﬁcant diﬀerence in cellular viability was observed in ALDH+ cells
in comparison to ALDH− cells, indicating that DSF inhibited the ALDH
+ population, reversed cisplatin-resistance of ALDH+ cells, and en-
hanced cisplatin cytotoxicity on ALDH+ cells (Fig. 6F).
4. Discussion
Since a remarkable series of transplant experiments initiated in the
Fig. 3. Flow cytometric analysis of cell cycle. A) Cells were treated with Cu2+ alone or DSF alone or DSF+Cu2+ for 72 h. The upper row (a and b) concentration is
1 μM DSF alone and 1 μM DSF+1 μM Cu2+ for IGROV1 and SKOV3IP1; 0.1 μM DSF alone and 0.1 μM DSF+1 μM Cu2+ for SKOV3. The lower row (c–f) con-
centration is control cells, 1 μM Cu2+ alone, 0.01 μM DSF alone, and 0.01 μM DSF+1 μM Cu2+ for three cell lines. Cells without any drug treatment were used as
control. Histograms were generated from propidium iodide-stained cells. The sub-G1 region was gated in the upper row of each cell line. The percentage of cells in
each cell cycle phase was quantitated and expressed as percent of all cells acquired. One representative of three independent experiments is shown. B–D) Graphical
representation of the percentage of cells in each cell cycle phase was quantitated and analyzed (n=3). Statistical analyses are based on three independent ex-
periments.
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Fig. 4. DSF+Cu2+ triggers ROS generation in ovarian cancer cell lines. A) Cancer cells were exposed to the indicated reagents and concentrations for 30min. The
dotted lines represent the untreated cells and the solid lines represent drug-treated cells, respectively. The relative ROS activity was calculated and normalized to
untreated control cells. One representative of three independent experiments is shown. B–D) Graphical representation of the relative ROS activity was quantitated
and analyzed (n= 3). E). ALDH+and ALDH- FACS-sorted cells from SKOV3 cell line were exposed to 10 μM DSF and 100 μM DSF. The relative ROS activity was
gated. One representative of three independent experiments is shown. F) Graphical representation of the relative ROS activity was quantitated and analyzed (n=3).
*P＜ 0.05, **P＜ 0.01, ***P＜ 0.001, ****P＜ 0.0001.
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Fig. 5. DSF sensitizes ovarian cancer cells to cisplatin treatment and induces more apoptosis. A) Cells were treated with either cisplatin alone or DSF alone or the
combinations at indicated concentrations for 72 h. Cellular viability was detected by MTT assay. B) Flow cytometric analysis exhibits the cellular apoptotic status.
Cells were treated with cisplatin alone or DSF alone or their combination for 72 h. LL, LR, UR and UL are representative for live cells, early apoptotic cells, late
apoptotic cells, and necrotic cells, respectively. One representative of three independent experiments is shown. C–E) Graphical representation of the statistical
analysis of the Annexin-V/PI dual staining results from 3 independent experiments. Cells without any drug treatment were used as control. DSF, Disulﬁram; CIS,
Cisplatin. *P＜ 0.05, **P＜ 0.01.
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Fig. 6. Characterization of ALDH+/− cells sorted from SKOV3 and treatment by cisplatin/DSF. A) Spheroid formation assay of FACS-sorted ALDH+ and ALDH−
cells. B) Quantitative analysis of spheroid formation of ALDH+/− cells. C) Colony formation assay of FACS-sorted ALDH+ and ALDH− cells. D) Quantitative
analysis of the number of colonies formed by ALDH+/− cells. E) ALDH+/− cells were treated with cisplatin and cell viability was analyzed by MTT assay. F) ALDH
+/− cells were treated with cisplatin combined with DSF and cell viability was analyzed by MTT assay.
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1950s [29], which reﬂected that only a limited number of cells, deﬁned
as cancer stem cells, are capable of initiating the tumor, increasing
evidence suggested that the characteristics of cancer stem cells might be
a promising explanation for the recurrence and metastasis of cancer
[30]. Therefore, identiﬁcation of drugs targeting CSCs is urgently re-
quired to improve the therapeutic outcomes in cancer and in particular
of ovarian cancer patients. Our study provides strong evidence that DSF
can inhibit cancer stem cells partly due to its modulation of ALDH and
ROS generation that can be enhanced by the addition of Cu2+.
This study shows that DSF itself exhibits dose-dependent and time-
dependent cytotoxicity in ovarian cancer cells and the DSF-mediated
cytotoxicity was enhanced by exogenous Cu2+ supplementation in
ovarian cancer cell lines. It has been proven that DSF can react with
redox-sensitive sulfhydryl groups (thiols) and binds Cu2+ [31]. Cu2+,
that can activate some critical proteins such as superoxide dismutase,
tyrosinase and cytochrome oxidase, plays an important role in biolo-
gical pathways in the human body [32]. Therefore, the Cu2+ con-
centration in the human body is tightly regulated. However, the
average concentration of Cu2+ in cancerous tissues is 1.7 ± 0.6 μg/g,
which is signiﬁcantly (P < 0.025) higher than the average con-
centration of 1.3 ± 0.3 μg/g in the normal tissues [33]. This may help
to enable selective treatment by DSF in cancer cells with enhancement
of cytotoxicity by the higher level of Cu2+ concentrations in cancers
while sparing normal tissues. One scenario could be that lipophilic DSF
can penetrate cancer cells and bind with intracellular Cu2+ and form
the DSF+Cu2+ complex (diethyldithio-carbomate (DDC)-Cu2+) which
is more cytotoxic and induces apoptosis. Studies are showing that
Cu2+-chelating DSF, but not DSF alone, evokes the unfolded protein
response and heat shock protein activation [34]. Another scenario is
that when exogenous Cu2+ was added into the medium, an instant and
short-term action between DSF and Cu2+ happened, producing some
certain chemical species, such as ROS, which in turn is toxic and causes
instant killing of cancer cells [35].
ALDH activity has been shown to be associated with the stem cell
population. Landen et al. have proven that ALDH+ ovarian cancer cells
are resistant to a wide range of classical cytotoxic anticancer drugs.
However, these cells can become re-sensitized to chemotherapy by
ALDH1A1 silencing using nanoliposomal siRNA in ovarian cancer cell
line SKOV3TRip2 and A2780cp20 [19]. Researches reported recently
demonstrated that DSF+Cu2+ treatment eliminated the stem cell-like
ALDH+cells pool in non-small cell lung cancer and multiple myeloma
[36,37]. Our study also showed that ALDH+ cells display stem-like
characteristics such as enhanced expression of stem cell transcription
factors (supplemental Fig. 1), clonogenicity, sustained proliferation,
and resistance to chemotherapy. Other than ALDH, the expression of
stemness-related transcription factors Oct3/4, Sox2, and Nanog were
also 2 to 10 fold higher in spheroid-derived compared to monolayer-
derived cells. Our results are in agreement with results from other labs
supporting that there is an enrichment of CSCs according to ALDH and
stemness-related transcription factor expression by anchorage-in-
dependent culture techniques and that therefore spheroid cell culture
models might be useful for evaluating CSCs [38,39]. Our study further
demonstrated that DSF with or without Cu2+ supplementation in-
hibited ALDH activity which is associated with many properties of
ovarian cancer stem cells, such as spheroid and colony formation, as
well as chemo-resistance, indicating that DSF may target ALDH+ stem-
like cells in ovarian cancer.
ROS are broadly deﬁned as oxygen-containing chemical species
with reactive properties. These include the superoxide (O2•−) and
hydroxyl (HO•) free radicals as well as non-radical molecules such as
hydrogen peroxide (H2O2) [40]. Cancer cells contain higher levels of
ROS due to rapid metabolism and signalling [41]. To compensate for
increased oxidative stress, cancer cells enhance their ability to detoxify
ROS by activating adaptive redox mechanisms, including increased
expression and activity of ROS-scavenging systems and antioxidants
[42]. Additionally, ALDH enzyme has been proven to act as a ROS
scavenger, and that could also explain why ALDH+ stem-like cells,
which have higher levels of ALDH, exhibit lower basal levels of ROS
[20]. Our data demonstrate that ROS, which contributes to a wide
variety of cell and tissue injury, may have a crucial role in DSF+Cu2+
induced cytotoxicity and apoptosis in ovarian cancer cell lines. DSF+
Cu2+ treatment increased intracellular ROS levels, which typically
triggered ALDH+ stem-like cells apoptosis. Simultaneously, DSF+
Cu2+ treatment inhibited ALDH enzyme activity and subsequently
leads to a loss of ALDH-mediated protection against oxidative stress.
These results are in agreement with the reports that ROS inhibitor (N-
acetylcysteine) could suppress antitumor potentiation of DSF by in-
hibiting H2O2 generation, and ROS promotor superoxide dismutases
(SODs) could increase the toxicity of DSF [43]. There was a similar
amount of ROS generated in ALDH+/− cells after DSF (10 μM) treat-
ment. A lower level of ROS in ALDH+ cells than ALDH- cells was
shown after 100 μM DSF treatment. One explanation could be that
ALDH+ cells were probably more vulnerable to DSF and were swiftly
killed by this concentration.
Further, we explored the combined eﬀect of DSF and cisplatin. We
choose cisplatin in this study because cisplatin can arrest the cell cycle
in the G2/M phase [20] while DSF induces ROS accumulation. There-
fore, these two drugs may potentiate the combination eﬀect based on
diﬀerent mechanisms. We found that DSF eﬀectively sensitized cancer
cells to cisplatin treatment even at its lower dose, and signiﬁcantly
enhanced cisplatin-induced apoptosis. Based on these results, we fur-
ther examined the resistance-reversing eﬀect of DSF on ALDH+ stem-
like cells. ALDH+ and ALDH− cells were explored after cell sorting to
avoid heterogeneous cell populations. Our results showed that ALDH+
cells displayed stem-like characteristics and were more resistant to
cisplatin treatment than ALDH− cells. However, ALDH+ cells ex-
hibited high sensitivity to DSF/cisplatin combination treatment, in-
dicating that DSF overcomes cisplatin resistance. This is in agreement
with a study by Song et al. [44] that cisplatin, in combination with DSF,
decreased the cell survival rate of cisplatin-resistant lung cancer cell
line A549DDP. Our results showed that DSF reversed the cisplatin re-
sistance of ALDH+ cells, leaving no diﬀerence between ALDH+ and
ALDH− cells when treated with cisplatin combined with DSF. The
explanation could be that DSF suppresses ALDH activity and stemness,
reverses cisplatin resistance on ALDH+ cells, and sensitizes a cisplatin-
resistant ALDH+ stem-like population to cisplatin treatment, conse-
quently improving the ability of cisplatin to kill resistant or less sensi-
tive cancer cells. Due to its chemo-sensitizing eﬀects, DSF is very pro-
mising to be combined with cisplatin-based chemotherapy to improve
the therapeutic impact.
Together, these results indicate that DSF with or without Cu2+
supplementation is toxic in ovarian cancer cell lines in vitro by me-
chanisms including targeting oxidative stress response and ALDH+
stem-like cells. There are additional eﬀects of Cu2+ described that
might support the induction of apoptosis and contribute to the eﬀect of
DSF. The clariﬁcation of their contribution, however, was not the scope
of this manuscript and should be investigated separately. DSF eﬀec-
tively suppressed ALDH activity and modulated ROS generation. It is
attractive to consider DSF as an adjuvant treatment combined with
cisplatin to establish a new chemotherapy protocol for targeting CSCs.
In this novel combination, DSF could suppress the ALDH activity and
sensitize the cisplatin-resistant ALDH+ stem-like population to cis-
platin treatment. At the same time, the cytotoxicity of cisplatin could be
increased once combined with DSF, inducing apoptosis in ovarian
cancer cells. However, more research is still needed to further explore
the eﬀect of DSF on tissues and primary tumors from patients.
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